[1] Etminan N, Chang HS, Hackenberg K, de Rooij NK, Vergouwen MDI, Rinkel GJE, Algra A. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population:a systematic review and meta-analysis[J]. JAMA Neurol, 2019, 76:588-597.
[2] Parlapiano G, Di Lorenzo F, Salehi LB, Ruvolo G, Novelli G, Sangiuolo F. Neurovascular manifestations in connective tissue diseases:the case of Marfan Syndrome[J]. Mech Ageing Dev, 2020, 191:111346.
[3] Kim ST, Cloft H, Flemming KD, Kallmes DF, Lanzino G, Brinjikji W. Increased prevalence of cerebrovascular disease in hospitalized patients with Marfan Syndrome[J]. J Stroke Cerebrovasc Dis, 2018, 27:296-300.
[4] Zhang H, Hudson FZ, Xu Z, Tritz R, Rojas M, Patel C, Haigh SB, Bordán Z, Ingram DA, Fulton DJ, Weintraub NL, Caldwell RB, Stansfield BK. Neurofibromin deficiency induces endothelial cell proliferation and retinal neovascularization[J]. Invest Ophthalmol Vis Sci, 2018, 59:2520-2528.
[5] Zhang X, Ares WJ, Taussky P, Ducruet AF, Grandhi R. Role of matrix metalloproteinases in the pathogenesis of intracranial aneurysms[J]. Neurosurg Focus, 2019, 47:E4.
[6] Samuel N, Radovanovic I. Genetic basis of intracranial aneurysm formation and rupture:clinical implications in the postgenomic era[J]. Neurosurg Focus, 2019, 47:E10.
[7] Hosseini V, Mallone A, Mirkhani N, Noir J, Salek M, Pasqualini FS, Schuerle S, Khademhosseini A, Hoerstrup SP, Vogel V. A pulsatile flow system to engineer aneurysm and atherosclerosis mimetic extracellular matrix[J]. Adv Sci (Weinh), 2020, 7:2000173.
[8] Hedtke T, Schräder CU, Heinz A, Hoehenwarter W, Brinckmann J, Groth T, Schmelzer CEH. A comprehensive map of human elastin cross-linking during elastogenesis[J]. FEBS J, 2019, 286:3594-3610.
[9] Alfieri M, Barbaro F, Consolini E, Bassi E, Dallatana D, Bergonzi C, Bianchera A, Bettini R, Toni R, Elviri L. A targeted mass spectrometry method to screen collagen types Ⅰ-Ⅴ in the decellularized 3D extracellular matrix of the adult male rat thyroid[J]. Talanta, 2019, 193:1-8.
[10] Ishiwata T, Tanabe N, Shigeta A, Yokota H, Tsushima K, Terada J, Sakao S, Morisaki H, Morisaki T, Tatsumi K. Moyamoya disease and artery tortuosity as rare phenotypes in a patient with an elastin mutation[J]. Am J Med Genet A, 2016, 170:1924-1927.
[11] Gholampour S, Mehrjoo S. Effect of bifurcation in the hemodynamic changes and rupture risk of small intracranial aneurysm[J]. Neurosurg Rev, 2020.[Epub ahead of print]
[12] Mannucci L, Luciano S, Salehi LB, Gigante L, Conte C, Longo G, Ferradini V, Piumelli N, Brancati F, Ruvolo G, Novelli G, Sangiuolo F. Mutation analysis of the FBN1 gene in a cohort of patients with Marfan Syndrome:a 10-year single center experience[J]. Clin Chim Acta, 2020, 501:154-164.
[13] Benarroch L, Aubart M, Gross MS, Arnaud P, Hanna N, Jondeau G, Boileau C. Reference expression profile of three FBN1 transcript isoforms and their association with clinical variability in Marfan Syndrome[J]. Genes (Basel), 2019, 10:128.
[14] Kim JH, Kim JW, Song SW, Ahn SJ, Park M, Park SK, Suh SH. Intracranial aneurysms are associated with Marfan Syndrome:single cohort retrospective study in 118 patients using brain imaging[J]. Stroke, 2021, 52:331-334.
[15] van den Berg JS, Limburg M, Hennekam RC. Is Marfan syndrome associated with symptomatic intracranial aneurysms[J]? Stroke, 1996, 27:10-12.
[16] Conway JE, Hutchins GM, Tamargo RJ. Marfan syndrome is not associated with intracranial aneurysms[J]. Stroke, 1999, 30:1632-1636.
[17] D'hondt S, Van Damme T, Malfait F. Vascular phenotypes in nonvascular subtypes of the Ehlers-Danlos syndrome:a systematic review[J]. Genet Med, 2018, 20:562-573.
[18] Errichiello E, Malara A, Grimod G, Avolio L, Balduini A, Zuffardi O. Low penetrance COL5A1 variants in a young patient with intracranial aneurysm and very mild signs of Ehlers-Danlos syndrome[J]. Eur J Med Genet, 2021, 64:104099.
[19] Ghali N, Baker D, Brady AF, Burrows N, Cervi E, Cilliers D, Frank M, Germain DP, Hulmes DJS, Jacquemont ML, Kannu P, Lefroy H, Legrand A, Pope FM, Robertson L, Vandersteen A, von Klemperer K, Warburton R, Whiteford M, van Dijk FS. Atypical COL3A1 variants (glutamic acid to lysine) cause vascular Ehlers-Danlos syndrome with a consistent phenotype of tissue fragility and skin hyperextensibility[J]. Genet Med, 2019, 21:2081-2091.
[20] Olubajo F, Kaliaperumal C, Choudhari KA. Vascular Ehlers-Danlos Syndrome:literature review and surgical management of intracranial vascular complications[J]. Clin Neurol Neurosurg, 2020, 193:105775.
[21] Maleszewski JJ, Miller DV, Lu J, Dietz HC, Halushka MK. Histopathologic findings in ascending aortas from individuals with Loeys-Dietz syndrome (LDS)[J]. Am J Surg Pathol, 2009, 33:194-201.
[22] Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type Ⅳ, the vascular type[J]. N Engl J Med, 2000, 342:673-680.
[23] North KN, Whiteman DA, Pepin MG, Byers PH. Cerebrovascular complications in Ehlers-Danlos syndrome type Ⅳ[J]. Ann Neurol, 1995, 38:960-964.
[24] Jutant EM, Girerd B, Jaïs X, Savale L, O'Connell C, Perros F, Sitbon O, Humbert M, Montani D. Pulmonary hypertension associated with neurofibromatosis type 1[J]. Eur Respir Rev, 2018, 27:180053.
[25] Solem EP, Primiano M, McQuillen MP, Zak Goelz M. Factors associated with parental knowledge of neurofibromatosis type 1(NF1):parental affected status and genetic counseling[J]. J Genet Couns, 2020, 29:1151-1158.
[26] Bernardo P, Cinalli G, Santoro C. Epilepsy in NF1:a systematic review of the literature[J]. Childs Nerv Syst, 2020, 36:2333-2350.
[27] Schievink WI, Riedinger M, Maya MM. Frequency of incidental intracranial aneurysms in neurofibromatosis type 1[J]. Am J Med Genet A, 2005, 134A:45-48.
[28] Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1[J]. Neurology, 2005, 64:553-555.
[29] Conway JE, Hutchins GM, Tamargo RJ. Lack of evidence for an association between neurofibromatosis type Ⅰ and intracranial aneurysms:autopsy study and review of the literature[J]. Stroke, 2001, 32:2481-2485.
[30] Wang XJ, Babameto M, Babovic-Vuksanovic D, Bowen JM, Camilleri M. Audit of gastrointestinal manifestations in patients with Loeys-Dietz syndrome and vascular Ehlers-Danlos syndrome[J]. Dig Dis Sci, 2020.[ Epub ahead of print]
[31] Luo X, Deng S, Jiang Y, Wang X, Al-Raimi AMA, Wu L, Liu X, Song Y, Chen X, Zhu F. Identification of a pathogenic TGFBR2 variant in a patient with Loeys-Dietz syndrome[J]. Front Genet, 2020, 11:479.
[32] Rodrigues VJ, Elsayed S, Loeys BL, Dietz HC, Yousem DM. Neuroradiologic manifestations of Loeys-Dietz syndrome type 1[J]. AJNR Am J Neuroradiol, 2009, 30:1614-1619.
[33] Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, De Backer JF, Oswald GL, Symoens S, Manouvrier S, Roberts AE, Faravelli F, Greco MA, Pyeritz RE, Milewicz DM, Coucke PJ, Cameron DE, Braverman AC, Byers PH, De Paepe AM, Dietz HC. Aneurysm syndromes caused by mutations in the TGF-beta receptor[J]. N Engl J Med, 2006, 355:788-798.
[34] Rangan GK, Raghubanshi A, Chaitarvornkit A, Chandra AN, Gardos R, Munt A, Read MN, Saravanabavan S, Zhang JQ, Wong AT. Current and emerging treatment options to prevent renal failure due to autosomal dominant polycystic kidney disease[J]. Expert Opin Orphan Drugs, 2020, 8:285-302.
[35] Dwivedi N, Tao S, Jamadar A, Sinha S, Howard C, Wallace DP, Field TA, Leask A, Calvet JP, Rao R. Epithelial vasopressin type-2 receptors regulate myofibroblasts by a YAP-CCN2-Dependent mechanism in polycystic kidney disease[J]. J Am Soc Nephrol, 2020, 31:1697-1710.
[36] Colbert GB, Elrggal ME, Gaur L, Lerma EV. Update and review of adult polycystic kidney disease[J]. Dis Mon, 2020, 66:100887.
[37] Perez JL, McDowell MM, Zussman B, Jadhav AP, Miyashita Y, McKiernan P, Greene S. Ruptured intracranial aneurysm in a patient with autosomal recessive polycystic kidney disease[J]. J Neurosurg Pediatr, 2018, 23:75-79.
[38] Nurmonen HJ, Huttunen T, Huttunen J, Kurtelius A, Kotikoski S, Junkkari A, Koivisto T, von Und Zu Fraunberg M, Kämäräinen OP, Lång M, Isoniemi H, Jääskeläinen JE, Lindgren AE. Lack of impact of polycystic kidney disease on the outcome of aneurysmal subarachnoid hemorrhage:a matched case-control study[J]. J Neurosurg, 2020:1-8.
[39] Zhou Z, Xu Y, Delcourt C, Shan J, Li Q, Xu J, Hackett ML. Is regular screening for intracranial aneurysm necessary in patients with autosomal dominant polycystic kidney disease:a systematic review and meta-analysis[J]? Cerebrovasc Dis, 2017, 44:75-82.
[40] Xu HW, Yu SQ, Mei CL, Li MH. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease[J]. Stroke, 2011, 42:204-206.
[41] Avetikov D, Buchanhenko OP, Shlykova O, Izmajlova OV, Lokes K, Klitynska OV, Vesnina L, Kajdashev IP. Presence of type 1 collagen alpha-2(COL1A2)(rs42524) gene polymorphism and scar tissue formation in different areas of head and neck[J]. Pesqui Bras Odontopediatria Clín Integr, 2020, 20:1-6.
[42] Brotis AG, Tasiou A, Giannis T, Paschalis A, Fountas KN. Collagen type-Ⅰ A2 gene polymorphisms and susceptibility to intracranial aneurysms:a meta-analysis of genetic association studies[J]. Int J Neurosci, 2018, 128:640-653.
[43] Gan Q, Liu Q, Hu X, You C. Collagen type Ⅰ alpha 2(COL1A2) polymorphism contributes to intracranial aneurysm susceptibility:a meta-analysis[J]. Med Sci Monit, 2017, 23:3240-3246.
[44] Kuivaniemi H, Prockop DJ, Wu Y, Madhatheri SL, Kleinert C, Earley JJ, Jokinen A, Stolle C, Majamaa K, Myllylä VV. Exclusion of mutations in the gene for type Ⅲ collagen (COL3A1) as a common cause of intracranial aneurysms or cervical artery dissections:results from sequence analysis of the coding sequences of type Ⅲ collagen from 55 unrelated patients[J]. Neurology, 1993, 43:2652-2658.
[45] Meng Q, Hao Q, Zhao C. The association between collagen gene polymorphisms and intracranial aneurysms:a meta-analysis[J]. Neurosurg Rev, 2019, 42:243-253.
[46] Hua T, Zhang D, Zhao YL, Wang S, Zhao JZ. Correlation of COL3A1 gene with type Ⅲ collagen stability in intracranial aneurysm[J]. Zhonghua Yi Xue Za Zhi, 2008, 88:445-448.
[47] Brega KE, Seltzer WK, Munro LG, Breeze RE. Genotypic variations of type Ⅲ collagen in patients with cerebral aneurysms[J]. Surg Neurol, 1996, 46:253-256.
[48] van den Berg JS, Pals G, Arwert F, Hennekam RC, Albrecht KW, Westerveld A, Limburg M. Type Ⅲ collagen deficiency in saccular intracranial aneurysms:defect in gene regulation[J]? Stroke, 1999, 30:1628-1631.
[49] Teixeira FS, Neufeld E, Kuster N, Watton PN. Modeling intracranial aneurysm stability and growth:an integrative mechanobiological framework for clinical cases[J]. Biomech Model Mechanobiol, 2020, 19:2413-2431.
[50] Onda H, Kasuya H, Yoneyama T, Takakura K, Hori T, Takeda J, Nakajima T, Inoue I. Genomewide-linkage and haplotype-association studies map intracranial aneurysm to chromosome 7q11[J]. Am J Hum Genet, 2001, 69:804-819.
[51] Jeon JP, Hong EP, Kim JE, Ha EJ, Cho WS, Son YJ, Bang JS, Oh CW. Genetic risk assessment of elastin gene polymorphisms with intracranial aneurysm in Koreans[J]. Neurol Med Chir (Tokyo), 2018, 58:17-22.
[52] Paterakis K, Koutsias S, Doxani C, Xanthopoulou P, Kokkali C, Mpoulimari I, Tziastoudi M, Karampelas I, Dardiotis E, Hadjigeorgiou G, Brotis AG, Zintzaras E. Variants of the elastin (ELN) gene and susceptibility to intracranial aneurysm:a synthesis of genetic association studies using a genetic model-free approach[J]. Int J Neurosci, 2017, 127:567-572.
[53] Hofer A, Hermans M, Kubassek N, Sitzer M, Funke H, Stögbauer F, Ivaskevicius V, Oldenburg J, Burtscher J, Knopp U, Schoch B, Wanke I, Hübner F, Deinsberger W, Meyer B, Boecher-Schwarz H, Poewe W, Raabe A, Steinmetz H, Auburger G. Elastin polymorphism haplotype and intracranial aneurysms are not associated in Central Europe[J]. Stroke, 2003, 34:1207-1211.
[54] Krex D, Schackert HK, Schackert G. Genesis of cerebral aneurysms: an update[J]. Acta Neurochir (Wien), 2001, 143:429-448.
[55] Xiao X, Ren J, Chen J, Liu Z, Tian Y, Nabar NR, Wang M, Hao L. LOX-related collagen crosslink changes act as an initiator of bone fragility in a ZDF rats model[J]. Biochem Biophys Res Commun, 2018, 495:821-827.
[56] Rodríguez M, Pascual G, Cifuentes A, Perez-Köhler B, Bellón JM, Buján J. Role of lysyl oxidases in neointima development in vascular allografts[J]. J Vasc Res, 2011, 48:43-51.
[57] Mäki JM, Räsänen J, Tikkanen H, Sormunen R, Mäkikallio K, Kivirikko KI, Soininen R. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice[J]. Circulation, 2002, 106:2503-2509.
[58] Hofer A, Ozkan S, Hermans M, Kubassek N, Sitzer M, Burtscher J, Knopp U, Schoch B, Wanke I, Huebner F, Raabe A, Steinmetz H, Auburger G. Mutations in the lysyl oxidase gene not associated with intracranial aneurysm in central European families[J]. Cerebrovasc Dis, 2004, 18:189-193.
[59] Ruigrok YM, Rinkel GJ. Genetics of intracranial aneurysms[J]. Stroke, 2008, 39:1049-1055.
[60] Sathyan S, Koshy L, Sarada Lekshmi KR, Easwer HV, Premkumar S, Alapatt JP, Nair S, Bhattacharya RN, Banerjee M. Lack of association of lysyl oxidase (LOX) gene polymorphisms with intracranial aneurysm in a south Indian population[J]. Mol Biol Rep, 2013, 40:5869-5874.
[61] Hong EP, Jeon JP, Kim SE, Yang JS, Choi HJ, Kang SH, Cho YJ. A novel association between lysyl oxidase gene polymorphism and intracranial aneurysm in Koreans[J]. Yonsei Med J, 2017, 58:1006-1011.
[62] Wei Y, Song S, Duan N, Wang F, Wang Y, Yang Y, Peng C, Li J, Nie D, Zhang X, Guo S, Zhu C, Yu M, Gan Y. MT1-MMP-activated liposomes to improve tumor blood perfusion and drug delivery for enhanced pancreatic cancer therapy[J]. Adv Sci (Weinh), 2020, 7:1902746.
[63] Chan ZC, Oentaryo MJ, Lee CW. MMP-mediated modulation of ECM environment during axonal growth and NMJ development[J]. Neurosci Lett, 2020, 724:134822.
[64] Bruno G, Todor R, Lewis I, Chyatte D. Vascular extracellular matrix remodeling in cerebral aneurysms[J]. J Neurosurg, 1998, 89:431-440.
[65] Kim SC, Singh M, Huang J, Prestigiacomo CJ, Winfree CJ, Solomon RA, Connolly ES Jr. Matrix metalloproteinase-9 in cerebral aneurysms[J]. Neurosurgery, 1997, 41:642-666.
[66] Sawyer DM, Pace LA, Pascale CL, Kutchin AC, O'Neill BE, Starke RM, Dumont AS. Lymphocytes influence intracranial aneurysm formation and rupture:role of extracellular matrix remodeling and phenotypic modulation of vascular smooth muscle cells[J]. J Neuroinflammation, 2016, 13:185.
[67] Krex D, Kotteck K, König IR, Ziegler A, Schackert HK, Schackert G. Matrix metalloproteinase-9 coding sequence single-nucleotide polymorphisms in caucasians with intracranial aneurysms[J]. Neurosurgery, 2004, 55:207-212.
[68] Makuszewska M, Bonda T, Cie?lińska M, Bialuk I, Winnicka MM, Niemczyk K. Expression of collagen type Ⅲ in healing tympanic membrane[J]. Int J Pediatr Otorhinolaryngol, 2020, 136:110196.
[69] Baker CJ, Fiore A, Connolly ES Jr, Baker KZ, Solomon RA. Serum elastase and alpha-1-antitrypsin levels in patients with ruptured and unruptured cerebral aneurysms[J]. Neurosurgery, 1995, 37:56-61.
[70] Marzatico F, Gaetani P, Tartara F, Bertorelli L, Feletti F, Adinolfi D, Tancioni F, Rodriguez y Baena R. Antioxidant status and alpha1-antiproteinase activity in subarachnoid hemorrhage patients[J]. Life Sci, 1998, 63:821-826.
[71] Schievink WI, Katzmann JA, Piepgras DG, Schaid DJ. Alpha-1-antitrypsin phenotypes among patients with intracranial aneurysms[J]. J Neurosurg, 1996, 84:781-784.
[72] Yoneyama T, Kasuya H, Akagawa H, Onda H, Nakajima T, Hori T, Inoue I, Lee JC, Yang TK, Kim CJ. Absence of alpha-1 antitrypsin deficiency alleles (S and Z) in Japanese and Korean patients with aneurysmal subarachnoid hemorrhage[J]. Stroke, 2004, 35:e376-378.
[73] Iakoubova OA, Tong CH, Rowland CM, Luke MM, Garcia VE, Catanese JJ, Moomiaie RM, Sotonyi P, Ascady G, Nikas D, Dedelias P, Tranquilli M, Elefteriades JA. Genetic variants in FBN-1 and risk for thoracic aortic aneurysm and dissection[J]. PLoS One, 2014, 9:e91437.
[74] Ruigrok YM, Rinkel GJ, van't Slot R, Wolfs M, Tang S, Wijmenga C. Evidence in favor of the contribution of genes involved in the maintenance of the extracellular matrix of the arterial wall to the development of intracranial aneurysms[J]. Hum Mol Genet, 2006, 15:3361-3368.
[75] Yoneyama T, Kasuya H, Onda H, Akagawa H, Jinnai N, Nakajima T, Hori T, Inoue I. Association of positional and functional candidate genes FGF1, FBN2, and LOX on 5q31 with intracranial aneurysm[J]. J Hum Genet, 2003, 48:309-314.